title: Metabolic positron emission tomography imaging of cancer: Pairing lipid metabolism with glycolysis.
abstract: The limitations of fluorine-18 fluorodeoxy-D-glucose (FDG) in detecting some cancers has prompted a longstanding search for other positron emission tomography (PET) tracers to complement the imaging of glycolysis in oncology, with much attention paid to lipogenesis based on observations that the production of various lipid and lipid-containing compounds is increased in most cancers. Radiolabeled analogs of choline and acetate have now been used as oncologic PET probes for over a decade, showing convincingly improved detection sensitivity over FDG for certain cancers. However, neither choline nor acetate have been thoroughly validated as lipogenic biomarkers, and while acetyl-CoA produced from acetate is used in de-novo lipogenesis to synthesize fatty acids, acetate is also consumed by various other synthetic and metabolic pathways, with recent experimental observations challenging the assumption that lipogenesis is its predominant role in all cancers. Since tumors detected by acetate PET are also frequently detected by choline PET, imaging of choline metabolism might serve as an alternative albeit indirect marker of lipogenesis, particularly if the fatty acids produced in cancer cells are mainly destined for membrane synthesis through incorporation into phosphatidylcholines. Aerobic glycolysis may or may not coincide with changes in lipid metabolism, resulting in combinatorial metabolic phenotypes that may have different prognostic or therapeutic implications. Consequently, PET imaging using dual metabolic tracers, in addition to being diagnostically superior to imaging with individual tracers, could eventually play a greater role in supporting precision medicine, as efforts to develop small-molecule metabolic pathway inhibitors are coming to fruition. To prepare for this advent, clinical and translational studies of metabolic PET tracers must go beyond simply estimating tracer diagnostic utility, and aim to uncover potential therapeutic avenues associated with these metabolic alterations.
authors.affiliation: Sandi A Kwee, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96822, United States.
authors.forename: Sandi A
authors.initials: SA
authors.lastname: Kwee
authors.affiliation: Sandi A Kwee, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96822, United States.
authors.forename: John
authors.initials: J
authors.lastname: Lim
keywords: Acetate; Cancer; Choline; Fatty acid metabolism; Glycolysis; Hepatocellular carcinoma; Lipogenesis; Positron emission tomography; Prostate cancer